NZ600768A - Human antibodies to human angiopoietin-like protein 4 - Google Patents

Human antibodies to human angiopoietin-like protein 4

Info

Publication number
NZ600768A
NZ600768A NZ600768A NZ60076810A NZ600768A NZ 600768 A NZ600768 A NZ 600768A NZ 600768 A NZ600768 A NZ 600768A NZ 60076810 A NZ60076810 A NZ 60076810A NZ 600768 A NZ600768 A NZ 600768A
Authority
NZ
New Zealand
Prior art keywords
human
protein
angiopoietin
antibodies
lcdr1
Prior art date
Application number
NZ600768A
Other languages
English (en)
Inventor
Jee H Kim
W Mark Sleeman
Gang Chen
Viktoria Gusarova
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NZ600768A publication Critical patent/NZ600768A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
NZ600768A 2009-12-24 2010-12-23 Human antibodies to human angiopoietin-like protein 4 NZ600768A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29009209P 2009-12-24 2009-12-24
US30635910P 2010-02-19 2010-02-19
US32831610P 2010-04-27 2010-04-27
US34927310P 2010-05-28 2010-05-28
US35612610P 2010-06-18 2010-06-18
PCT/US2010/061987 WO2011079257A2 (en) 2009-12-24 2010-12-23 Human antibodies to human angiopoietin-like protein 4

Publications (1)

Publication Number Publication Date
NZ600768A true NZ600768A (en) 2014-09-26

Family

ID=43629324

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600768A NZ600768A (en) 2009-12-24 2010-12-23 Human antibodies to human angiopoietin-like protein 4

Country Status (30)

Country Link
US (2) US8354103B2 (enExample)
EP (1) EP2516466B1 (enExample)
JP (2) JP6000855B2 (enExample)
KR (1) KR101842570B1 (enExample)
CN (1) CN102741284A (enExample)
AR (1) AR079708A1 (enExample)
AU (1) AU2010336369C1 (enExample)
BR (1) BR112012017765A2 (enExample)
CA (1) CA2785158C (enExample)
CY (1) CY1118898T1 (enExample)
DK (1) DK2516466T3 (enExample)
ES (1) ES2628135T3 (enExample)
HR (1) HRP20170524T1 (enExample)
HU (1) HUE034722T2 (enExample)
IL (1) IL220402A (enExample)
JO (1) JO3274B1 (enExample)
LT (1) LT2516466T (enExample)
MX (1) MX337082B (enExample)
NZ (1) NZ600768A (enExample)
PL (1) PL2516466T3 (enExample)
PT (1) PT2516466T (enExample)
RS (1) RS56009B1 (enExample)
RU (1) RU2580045C2 (enExample)
SG (1) SG181784A1 (enExample)
SI (1) SI2516466T1 (enExample)
SM (1) SMT201700280T1 (enExample)
TW (1) TWI488643B (enExample)
UY (1) UY33144A (enExample)
WO (1) WO2011079257A2 (enExample)
ZA (1) ZA201204507B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
BR112014006394A2 (pt) * 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013155512A2 (en) * 2012-04-13 2013-10-17 The Johns Hopkins University Treatment of ischemic retinopathies
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
MX2015016978A (es) 2013-06-10 2016-04-25 Merck Sharp & Dohme Proteinas de union a antigeno neutralizantes de citomegalovirus.
KR101538787B1 (ko) * 2013-06-27 2015-07-22 인하대학교 산학협력단 췌장염 진단용 바이오 마커 조성물
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
EP3447493B1 (en) * 2014-01-07 2020-05-13 Bioatla, LLC Proteins targeting orthologs
WO2016020880A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
US9556225B2 (en) * 2014-10-15 2017-01-31 Uniao Quimica Farmaceutica Nacional S/A Peptide stimulator of cell survival and proliferation
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
EA201991203A1 (ru) 2016-11-17 2019-10-31 Способы лечения ожирения антителами к angptl8
EP3565598A4 (en) 2017-01-03 2020-10-28 Trellis Bioscience, LLC NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
JP2022525703A (ja) * 2019-03-20 2022-05-18 ジャベリン・オンコロジー・インコーポレイテッド 抗ａｄａｍ１２抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法
KR20220012856A (ko) 2019-08-29 2022-02-04 레메젠 코, 리미티드 항 ｐｄ―ｌ１ 항체 및 그의 용도
CA3164050A1 (en) * 2019-12-09 2021-06-17 Empirico Inc. Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases
BR112022017048A2 (pt) 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
WO2022006555A2 (en) * 2020-07-02 2022-01-06 Gigagen, Inc. BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
JP2023533253A (ja) * 2020-07-02 2023-08-02 マブリティクス， インコーポレイテッド 細胞結合タンパク質および使用の方法
CN119343148A (zh) * 2022-06-10 2025-01-21 南洋理工大学 使用angptl4拮抗剂治疗肝纤维化、炎症或相关疾病的方法
EP4566632A1 (en) * 2022-08-02 2025-06-11 Nona Biosciences (Suzhou) Co., Ltd. Msln antibody-drug conjugate
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
WO2006074228A1 (en) * 2005-01-07 2006-07-13 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )
CA2630839C (en) 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
AU2007227251A1 (en) * 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Also Published As

Publication number Publication date
JP2015145424A (ja) 2015-08-13
AU2010336369B2 (en) 2015-06-04
DK2516466T3 (en) 2017-05-15
SI2516466T1 (sl) 2017-06-30
US20130266574A1 (en) 2013-10-10
CN102741284A (zh) 2012-10-17
CA2785158C (en) 2018-07-24
MX337082B (es) 2016-02-11
KR20120104613A (ko) 2012-09-21
JP6000855B2 (ja) 2016-10-05
UY33144A (es) 2011-06-30
CA2785158A1 (en) 2011-06-30
MX2012007460A (es) 2012-08-23
LT2516466T (lt) 2017-05-25
RS56009B1 (sr) 2017-09-29
AR079708A1 (es) 2012-02-15
ZA201204507B (en) 2013-02-27
TW201132354A (en) 2011-10-01
BR112012017765A2 (pt) 2017-06-20
HUE034722T2 (en) 2018-02-28
CY1118898T1 (el) 2018-01-10
US9120851B2 (en) 2015-09-01
RU2580045C2 (ru) 2016-04-10
PL2516466T3 (pl) 2017-09-29
HRP20170524T1 (hr) 2017-06-02
SMT201700280T1 (it) 2017-07-18
AU2010336369C1 (en) 2015-08-27
RU2012131547A (ru) 2014-01-27
EP2516466A2 (en) 2012-10-31
JO3274B1 (ar) 2018-09-16
WO2011079257A2 (en) 2011-06-30
IL220402A (en) 2016-10-31
ES2628135T3 (es) 2017-08-01
PT2516466T (pt) 2017-06-06
WO2011079257A3 (en) 2011-08-18
TWI488643B (zh) 2015-06-21
SG181784A1 (en) 2012-07-30
JP2013515486A (ja) 2013-05-09
US8354103B2 (en) 2013-01-15
KR101842570B1 (ko) 2018-03-28
US20110159015A1 (en) 2011-06-30
AU2010336369A1 (en) 2012-07-12
EP2516466B1 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ628943A (en) Human antibodies to clostridium difficile toxins
NZ608660A (en) Anti-cd48 antibodies and uses thereof
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
NZ600512A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
NZ603529A (en) Antibodies to human gdf8
NZ598391A (en) Anti-hepcidin antibodies and uses thereof
NZ714313A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
NZ583605A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
NZ603607A (en) Cgrp antibodies
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
NZ603972A (en) Anti-fgfr2 antibodies
NZ594682A (en) Fully human antibodies specific to cadm1
PE20191408A1 (es) Proteinas de union a antigeno st2
NZ592436A (en) Treatment with anti-alpha2 integrin antibodies
NZ590863A (en) Anti-hepcidin-25 selective antibodies and uses thereof
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
IL259036A (en) asct2-specific binding molecules and their uses

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 DEC 2017 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20150325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 DEC 2018 BY ANAQUA SERVICES

Effective date: 20171120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 DEC 2019 BY ANAQUA SERVICES

Effective date: 20181120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 DEC 2020 BY ANAQUA SERVICES

Effective date: 20191120

LAPS Patent lapsed